Assessing oral delivery of biopharmaceuticals

Challenge An incoming lead investor needed to assess a proprietary platform technology for the oral delivery of biological drugs.
Learn More

Providing clinical due diligence of a novel biologic to treat respiratory disease

Challenge A pharma company looking to purchase an asset needed a respiratory consultant to conduct clinical due diligence of a Phase II biologic designed to treat a respiratory condition.
Learn More

Providing Phase lll-ready radiolabeled antibody due diligence

Challenge A well-capitalized strategic investor looking to enter the radiopharmaceuticals market wanted to conduct clinical due diligence on a novel radioisotope-conjugated antibody designed to treat...
Learn More

Providing technical due diligence on a Rubidium-82 radionuclide generator

Challenge Our client was looking to build a capability in radionucleotide imaging and was seeking merger and acquisition opportunities in Europe and the US. One target company was developing a new...
Learn More

Radionucleotide imaging due diligence

Challenge A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Providing scientific and immunological mechanism of action due diligence for a big pharma client

Challenge A major pharma company needed scientific and immunology due diligence support on a novel cyclic peptide, targeting the complement cascade system.
Learn More

Providing pharmacovigilance due diligence of a Phase lll oncology program

Challenge A major pharmaceutical company asked us for support in the medical safety and pharmacovigilance due diligence and assessment of a Phase III in-licensing opportunity. The drug in question...
Learn More

Providing due diligence in neurology

Challenge A venture capital investor needed an assessment of the technical, regulatory and market risks in a neuroscience specialty pharma company developing a range of products through the 505...
Learn More

Assessing commercial viability of biosimilars

Challenge A European pharma company seeking to license a development-stage follow-on biologic needed to assess the commercial potential of a second-generation antibody against a validated oncology...
Learn More

Assessing an ophthalmic market opportunity

Challenge A leading research institute developing novel approaches for the production of ophthalmic treatments wanted to conduct a market and competitive assessment of the current supplier base and...
Learn More

Independent review of oncology clinical trial data

Challenge A biopharmaceutical company asked us to provide an independent review of data from a recently completed clinical trial. We were to provide a summary report for the company’s management and...
Learn More

Consulting on monoclonal antibodies to treat bacterial infections

Challenge An established US biotech company was looking for a team of expert antibody consultants to help them understand the potential of monoclonal antibodies (mAbs) to treat bacterial infections.
Learn More